New drugs for pulmonary hypertension

Caroline O&Connell, Dermot S. O&Callaghan, Sean Gaine

Source: Eur Respir Monogr 2012; 57: 233-246
Journal Issue: Pulmonary Hypertension
Disease area: Pulmonary vascular diseases

Congress or journal article abstractFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Caroline O&Connell, Dermot S. O&Callaghan, Sean Gaine. New drugs for pulmonary hypertension. Eur Respir Monogr 2012; 57: 233-246

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Looking to the future: a new decade of pulmonary arterial hypertension therapy
Source: Eur Respir Rev 2011; 20: 262-269
Year: 2011



Role of tyrosine phosphatase in the modulation of pulmonary vascular tone
Source: Eur Respir J 2002; 19: 525-529
Year: 2002



Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology
Year: 2007


The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017

Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007



Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity
Source: Eur Respir J 2004; 24: Suppl. 48, 36s
Year: 2004

The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan
Source: Annual Congress 2010 - Airway smooth muscle cells
Year: 2010

Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts
Source: Eur Respir J 2008; 32: 555-562
Year: 2008



Angiotensin II and hypoxia synergistically induce proliferation in pulmonary artery fibroblasts by a PI-3K and PKC-signaling pathway through HIF-1 a and upregulation of angiotensin II-receptors type I
Source: Eur Respir J 2002; 20: Suppl. 38, 378s
Year: 2002

Selective versus non-selective endothelin receptor antagonists
Source: Annual Congress 2005 - New treatments in pulmonary hypertension
Year: 2005

Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007


Gene transfer of a β-adrenergic receptor kinase inhibitor up-regulated levels of β-adrenergic receptor and cAMP in asthmatic murine lung
Source: Eur Respir J 2005; 26: Suppl. 49, 580s
Year: 2005

Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2004 - Pulmonary fibrosis - new insights
Year: 2004


Protease activated receptor-1 (PAR-1) stimulation leads to αvβ6 integrin mediated TGFβ activation via rho kinase
Source: Eur Respir J 2005; 26: Suppl. 49, 238s
Year: 2005

Endothelin receptor antagonists (ERAs) neutralize LPS-induced cytokine release from pulmonary vascular smooth muscle cells (PVSMCs) by down-regulation of CD14
Source: Annual Congress 2013 –Airway smooth muscle and cell biology
Year: 2013

The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit
Source: Eur Respir J 2001; 18: Suppl. 33, 35s
Year: 2001

Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008



Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020


MAP kinase phosphatase 1 mediates glucocorticoid inhibition of CD38 expression in human airway smooth muscle
Source: Annual Congress 2008 - Basic science in asthma and COPD II
Year: 2008

Effect of rifampin, a potent organic-anion-transporting polypeptide inhibitor (OATPi), on the PK of BMS-986278, a lysophosphatidic acid receptor (LPA1) antagonist
Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children
Year: 2020